This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Verastem Reports Data On Focal Adhesion Kinase Program At The 2012 EORTC Symposium On Molecular Targets And Cancer Therapeutics

Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, reported new data from its focal adhesion kinase (FAK) inhibition program and commented on encouraging clinical data on FAK inhibition presented at the 2012 EORTC Symposium on Molecular Targets and Cancer Therapeutics being held in Dublin, Ireland.

Data presented by Verastem in breast cancer models lacking the tumor suppressor Merlin demonstrate that FAK inhibition effectively reduces cancer stem cells in vitro and in vivo. Oral administration of a FAK inhibitor as a single agent was shown to induce tumor regression in a Merlin-negative breast cancer mouse model. These data extend previous research from Verastem, which demonstrated similar inhibition of cancer stem cells and strong single agent efficacy in Merlin-negative mesothelioma models.

Several groups presented data at the conference on the use of FAK inhibitors for treatment of cancer. In one clinical study by GlaxoSmithKline, researchers demonstrated that Merlin loss may identify a subset of patients with improved progression free survival in response to FAK inhibition. “These results provide important clinical validation of our internal research demonstrating enhanced sensitivity of Merlin-negative mesothelioma to FAK inhibitors,” said Jonathan Pachter, Ph.D., Verastem Vice President and Head of Research.

Verastem anticipates initiating a potentially pivotal study in mesothelioma midyear 2013.

“The sum of the data on development of FAK inhibitors presented at this conference is very promising,” said Professor Dean Fennell, Chair of Thoracic Medical Oncology, University of Leicester. “In particular, GSK reported in a Phase 1 trial novel activity of a FAK inhibitor in mesothelioma, where treatment in the second and third-line setting resulted in a median progression free survival of 17.7 weeks.”

The largest clinical trial to date in malignant pleural mesothelioma was a 2011 Phase 3 study of Zolinza ® as a second- and third-line treatment conducted by Merck in 660 patients. In this study, a median progression free survival of only 6 weeks was observed.

“Interestingly, loss of the tumor suppressor Merlin correlated with increased clinical sensitivity to FAK inhibition,” Prof. Fennell continued. “A subset of patients with Merlin negative mesothelioma had more than double the median progression free survival of 24.1 weeks versus 11.4 weeks for the Merlin positive group. These early results suggest that a targeted therapy, particularly when used in combination with a specific biomarker, has the potential to significantly improve treatment of this aggressive and deadly disease.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 0.00%
FB $118.06 0.00%
GOOG $695.70 0.00%
TSLA $222.56 0.00%
YHOO $36.00 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs